Market Place
Sourcing Support
AbbVie: Atogepant Long-Term Migraine Data At AAN
12 Apr 2024 //
PR NEWSWIRE
AbbVie Announces European Commission Approval of AQUIPTA for Migraine
18 Aug 2023 //
PRESS RELEASE
CHMP recommends AbbVie`s migraine drug, GSK`s anemia treatment
24 Jun 2023 //
ENDPTS
AbbVie reveals results from pivotal atogepant trial
21 Apr 2023 //
PHARMA TIMES
AbbVie`s Qulipta gains approval to prevent chronic migraines
19 Apr 2023 //
ENDPTS
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
17 Apr 2023 //
PRESS RELEASE
AbbVie`s Qulipta Outperforms Pfizer`s Nurtec ODT in Preventive Migraine Space
16 Mar 2023 //
PR NEWSWIRE
AbbVie Submits MAA to EMA for Atogepant for Preventive Treatment of Migraine
18 Jul 2022 //
PRNEWSWIRE
AbbVie Submits sNDA to U.S. FDA for Atogepant to Support Label Expansion
22 Jun 2022 //
PRESS RELEASE
AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment
11 Mar 2022 //
BIOSPACE
AbbVie follows Biohaven into oral CGRP for migraine prevention
29 Sep 2021 //
FIERCEPHARMA
AbbVie`s oral migraine treatment atogepant nears FDA decision
20 Aug 2021 //
FIERCEBIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.